Open Access

Significant improvement of direct reprogramming efficacy of fibroblasts into progenitor endothelial cells by ETV2 and hypoxia

  • Phuc Van Pham1Email author,
  • Ngoc Bich Vu1,
  • Hoa Trong Nguyen1,
  • Oanh Thuy Huynh1 and
  • Mai Thi-Hoang Truong1
Contributed equally
Stem Cell Research & Therapy20167:104

https://doi.org/10.1186/s13287-016-0368-2

Received: 27 April 2016

Accepted: 18 July 2016

Published: 4 August 2016

Abstract

Background

Endothelial progenitor cell (EPC) transplantation is a promising therapy for ischemic diseases such as ischemic myocardial infarction and hindlimb ischemia. However, limitation of EPC sources remains a major obstacle. Direct reprogramming has become a powerful tool to produce EPCs from fibroblasts. Some recent efforts successfully directly reprogrammed human fibroblasts into functional EPCs; however, the procedure efficacy was low. This study therefore aimed to improve the efficacy of direct reprogramming of human fibroblasts to functional EPCs.

Methods

Human fibroblasts isolated from foreskin were directly reprogrammed into EPCs by viral ETV2 transduction. Reprogramming efficacy was improved by culturing transduced fibroblasts in hypoxia conditions (5 % oxygen). Phenotype analyses confirmed that single-factor ETV2 transduction successfully reprogrammed dermal fibroblasts into functional EPCs.

Results

Hypoxia treatment during the reprogramming procedure increased the efficacy of reprogramming from 1.21 ± 0.61 % in normoxia conditions to 7.52 ± 2.31 % in hypoxia conditions. Induced EPCs in hypoxia conditions exhibited functional EPC phenotypes similar to those in normoxia conditions, such as expression of CD31 and VEGFR2, and expressed endothelial gene profiles similar to human umbilical vascular endothelial cells. These cells also formed capillary-like networks in vitro.

Conclusion

Our study demonstrates a new simple method to increase the reprogramming efficacy of human fibroblasts to EPCs using ETV2 and hypoxia.

Keywords

Direct reprogrammingEndothelial progenitor cellsFibroblastETV2Epigenetic reprogramming

Background

Endothelial progenitor cells (EPCs) trigger angiogenesis and vasculogenesis, and thus have been used in the treatment of diseases related to ischemia. EPCs have been isolated from peripheral blood [15], bone marrow [68], and umbilical cord blood [912]. Several studies have demonstrated successful preclinical application of EPCs in various disease models, such as rat myocardial infarction [1315], murine hindlimb ischemia [16], rat ischemic myocardium [17], dermal wound healing [18], and mouse ovarian grafts [19]. A recent study showed that EPC transplantation could increase neovascularization in porcine models [20]. Clinically, EPC transplantation can improve cardiovascular outcomes. In a phase I/II clinical trial of 24 patients [21] followed by a phase IIb trial with 167 patients [22], almost all patients subjected to EPC transplantation showed improved angina frequency and exercise tolerance. In another phase III trial of 444 patients, CD34 cell transplantation could improve the functional capacity in patients with refractory angina [23]. In addition to coronary artery diseases, other pilot studies have also used autologous CD34 to treat critical limb ischemia and showed reduced amputation rates in critical limb ischemic patients [24]. Several studies have also genetically modified EPCs by transfecting cells with genes to increase the treatment efficacy, such as hTERT-transfected EPCs for ischemic myocardium of rats [25], vascular endothelial growth factor (VEGF)-transfected EPCs for myocardial infarction [26], and VEGF and heme oxygenase-1-transfected EPCs for the hindlimb ischemia mice model [27, 28]. Human cord blood endothelial progenitors could also promote postischemic angiogenesis in an immunocompetent mouse model [29].

Successful application of EPC treatments in the clinic, however, has encountered several obstacles, such as limited EPC sources, low numbers of cells, and low proliferation. The number of EPCs in peripheral blood and bone marrow is extremely low [5, 30]. Therefore, deriving endothelial cells as well as EPCs from pluripotent stem cells was studied [3133]. Although EPCs derived from embryonic stem cells were suggested to be a more promising therapy compared with umbilical cord EPCs [34], this application has not been translated to the clinic owing to the risk of pluripotent stem cells stimulating tumor formation [35, 36]. Current research has thus focused on human fibroblasts (HFs) as a cell source for reprogramming to EPCs.

The first effort towards direct reprogramming of fibroblasts to EPCs was performed by Margariti et al. [37]. The authors developed a method to generate partial-induced pluripotent stem cells by transferring four reprogramming factors (OCT4, SOX2, KLF4, and c-MYC) to HFs for 4 days. These partial-induced pluripotent stem cells were capable of differentiating into endothelial cells in response to defined media and culture conditions [37]. However, although the endothelial cells obtained could not form tumors, these cells carried oncogenes such as Sox-2 [37]. Li et al. and Han et al. successfully removed the Sox-2 gene in a revised version of the procedure and instead only used two genes (Oct4 and Klf4) in combination with soluble factors [38] or Foxo1, Er71, Klf2, Tal1, and Lmo2 [39]. These studies used a mixture of factors to induce fibroblasts to EPCs and involved complex procedures with low efficacy.

Recently, ETV2 was reported as a single factor that could induce direct reprogramming of fibroblasts into EPCs [40, 41] and of amniotic cells into EPCs [42]. In fact, ETV2 is a master gene that regulates various signaling pathways and functions as an essential regulator for vasculogenesis and hematopoiesis. ETV2 and GATA2 bind to the promoter of SPI1 and regulate its expression during embryogenesis [43]. ETV2 regulates cardiac development [44], and vascular regeneration [45]. However, the direct reprogramming of ETV2 transduction was low (about 1 %) [41]. Several studies have reported that hypoxia could improve reprogramming of cells. Foja et al. [46] showed that hypoxia improved the reprogramming of MSCs into induced pluripotent stem cells (iPSCs). Adipose stem cells were also stimulated for reprogramming to iPSCs by hypoxia [47]. Hypoxia also enhanced the reprogramming of fibroblasts into iPSCs [48] and dental pulp cells into iPSCs [49]. This study therefore examined the potential enhancement of direct reprogramming efficacy to EPCs by single-factor ETV2 under hypoxia treatment.

Methods

Isolation and culture of human dermal fibroblasts and cell culture

Foreskin was collected from a donor who provided a consent form at the hospital. Foreskin was stored in PBS solution at 4 °C and transferred to the laboratory for isolation and culture of fibroblasts, as described in previous studies [50]. Briefly, the samples were cut into small pieces, placed into wells, and allowed to adhere for 5 min at room temperature. DMEM medium supplemented with 10 % FBS, 1× anti-mitotic-mycotic was then added to the wells and the cultures were maintained at 37 °C, 5 % CO2. The cultures were subcultured when cells reached 70–80 % confluence. HFs were continuously subcultured to third passages and these cells were used in further experiments. Human umbilical vein endothelial cells (HUVECs) were purchased from Lifetechnologies (code number C0035C; Carlsbad, CA, USA).

Lentivirus production

The human ETV2 expression vector (pF1KB9707) was purchased from Addgene (Cambridge, MA, USA). ETV2 was cloned into the vector backbone pSIN4-EF1alpha-IRES-Puro (Plasmid #61061; Addgene, Cambridge, MA, USA) to generate pSIN4-EF1a-ETV2-IRES-Puro. All of the coding sequences in the expression vector were confirmed with a GenomeLab System (Beckman Coulter, Brea, CA, USA). The ETV2 vector was then transfected into HEK293T cells along with pCMV-VSV-G-RSV-Rev and pCMV-dR8.2 (Addgene). Eighteen hours after transfection, the medium was replaced with fresh culture medium, and 48 h later the lentivirus-containing medium was collected, passed through a 0.45-μm filter, and concentrated using centrifugation (8400 × g at 4 °C for 16 h). The lentivirus pellets were resuspended in PBS at 107 IFUs/ml.

ETV2 transduction of cells

HFs were plated on 12-well plates at 7 × 104 cells per well and 24 h later were infected with the 10 μl concentrated lentivirus particles with 5 μg/ml protamine. Plates were grouped into two groups: normoxia and hypoxia. The normoxia group was incubated in 20 % O2, 5 % CO2, 37 °C, while the hypoxia group was incubated in 5 % O2, 5 % CO2, 37 °C. Another 48 h later, cells were washed twice with PBS and then cultured on 6-cm dishes coated with Cellstart (Lifetechnologies) in EGM-2 medium under normoxia or hypoxia conditions.

VEGF treatment

Anti-VEGF monoclonal antibody was added into the medium at 10 ng/ml before culturing cells under hypoxia conditions. The medium was replaced after 3 days with medium containing an anti-VEGF antibody (P931; Lifetechnologies). In the normoxia group, recombinant protein VEGF at 10 ng/ml was added into the culture medium. The medium was replaced for 3 days with fresh medium containing recombinant VEGF. Cells were then infected with ETV2 virus. After 21 days, the samples were subjected to experimental analyses.

Quantitative RT-PCR

Total RNA was extracted using Trizol according to the manufacturer’s instructions. PCR analysis was performed using one-step real-time RT-PCR and the SYBR® Green Quantitative RT-qPCR Kit (Sigma-Aldrich, St. Louis, MO, USA) on a Realplex Mastercycler (Eppendorf). Relative gene expression levels were normalized by comparison with GAPDH. Gene-specific primer pairs are presented in Table 1.
Table 1

Gene-specific primers used for quantitative RT-PCR

Gene

Forward primer

Reverse primer

EFNB2

TCCTCAACTGTGCCAAACCAGACCAA

AGGCCCTCCAAAGACCCATTTGATGT

EPHB4

AAGAAAGTTTCGCAGCCGCTGGCTTT

TCATGTGCTGGACACTGGCCAAGATT

HEY1

AAATGCTGCATACGGCAGGAGGGAAA

ATAACGCGCAACTTCTGCCAGGCAT

JAG1

TTTGGAGCGACCTGTGTGGATGAGA

TGGTGATGCAAGGTCTCCCTGAAACT

NR2F2

GGACCACATACGGATCTTCCAAGAGCAA

TTTCCTGCAAGCTTTCCACATGGGCT

NRP2

AGGAGCCCTGTGGTTGGATGTATGA

TGTCACTCTGCAGCCGCAAGAAAT

PROX1

ACCCGTTATCCCAGCTCCAATATGCT

ATCGTTGATGGCTTGACGTGCGTA

SOX18

TGAACGCCTTCATGGTGTGGGCAAA

CGCGTTCAGCTCCTTCCACGCTTT

Capillary-like structure formation assay

Cells (2 × 104) were seeded on 96-well flat-bottom plates coated with 30 μl Matrigel (Lifetechnologies) and cultured in EGM-2 medium. Eighteen hours after incubation, capillary-like structures were observed under an Axiovert microscope (Carl-Zeiss, Oberkochen, Germany).

Flow cytometry and cell sorting

Cells were detached using TrypLe (Lifetechnologies), resuspended in PBS-containing 2 % FBS and 2 mM EDTA, and then stained with fluorochrome-leveled mAbs for 20 min on ice. Living cells were identified by 7-AAD exclusion and then analyzed for cell surface marker expression using a FACSCalibur flow cytometer (BD Bioscience). Fifteen and 25 days after lentivirus gene transduction, cells were labeled as already described and sorted using a FACSJazz (BD Bioscience). Collected events were analyzed using FACS software.

VEGF measurement

The supernatant was collected after changing with fresh medium for 48 h and stored at −20 °C until analysis. VEGF measurement was performed using a human VEGF ELISA kit (Abcam, Cambridge, UK).

Statistical analysis

Statistical analyses of all endpoints were performed using the two-sided Student’s t test or one-way analysis of variance. All data are presented as mean ± SD. p < 0.05 was considered statistically significant. Data were analyzed with Prism 6.0 software.

Results

Isolation and culture of HFs

Dermal HFs were isolated by culture expansion from dermal tissues. HFs appeared in culture at day 4 with a spindle shape (Fig. 1a). At day 14, the fibroblasts reached 70–80 % confluency (Fig. 1b). The cultures were subcultured to expand the fibroblast population and eliminate keratinocyte contamination. At the fifth passage, the fibroblasts were homogeneous in shape under a microscope (Fig. 1c). These cells were stored in liquid nitrogen for further experiments.
Fig. 1

Isolation and culture of HFs from human skin. (a) Skin tissue was cultured to isolate the fibroblasts. These fibroblasts were subcultured to the second passage (b) and fifth passage (c) for further use

ETV2 transduced fibroblasts contain CD31-positive cells

To establish EPCs, HFs were transduced with ETV2 virus for 14 days, after which cells were examined for the EPC phenotype. Using an inverted microscope, we observed some clusters of fibroblasts with four to five cells with a round shape (Fig. 2e). We also examined the morphology of cells in both hypoxia and normoxia conditions, and observed more clusters in the hypoxia group (Fig. 2i) compared with the normoxia group.
Fig. 2

Expression of CD31. HFs did not express the CD31 marker (ad). Some cells expressed CD31 in normoxia conditions and transduction with ETV2 (eh) and in transduction with ETV2 and hypoxia conditions (il). Almost all HUVECs expressed CD31 (mp). HUVEC human umbilical vein endothelial cell

To confirm these round cells as EPCs, we evaluated CD31 expression. The results showed that round cells in both the normoxia and hypoxia groups were positive for CD31 (Fig. 2e–h and Fig. 2i–l), while spindle-like cells were negative for CD31. Fibroblasts (100 %) were negative for CD31 expression (Fig. 2a–d), while 100 % of HUVECs, used as a positive control, were positive for CD31 expression (Fig. 2m–p).

ETV2 combined with hypoxia improved reprogramming efficacy compared with ETV2 transduction alone

To compare the effects of normoxia and hypoxia on the efficacy of reprogramming fibroblasts to EPCs, samples transduced for 14 days were analyzed for CD31 expression by flow cytometry. The results showed that ETV2-transduced fibroblasts under both normoxia and hypoxia conditions contained a small population of CD31-positive cells. However, in the hypoxia group the reprogramming efficacy toward EPCs significantly increased to 7.52 ± 2.31 %, compared with 1.21 ± 0.61 % in the normoxia group (p > 0.05). We did not observe any CD31-positive cells in the negative control (fibroblasts) (Fig. 3a), and confirmed 100 % of HUVECs positive for CD31 expression. Similarly, ETV2 virally transduced fibroblast samples showed a significant increase in the cell population positive for VEGFR2, and an increase in cells positive for both CD31 and VEGFR2 (Fig. 3b, c).
Fig. 3

Hypoxia improves the reprogramming of ETV2 of fibroblasts into EPCs. HFs were negative for both CD31 and VEGFR2 (a), while ETV2 transduced cells contained a small population of CD31+VEGFR2+/− (b). In the hypoxia condition, ETV2 transduced fibroblasts significantly increased to form CD31+VEGFR2+ cells (c). To evaluate some cell characteristics from two cell populations, all CD31+ cells in the groups of normoxia and transduction with ETV2 (d) and of hypoxia and transduction with ETV2 (e) were sorted

To evaluate the induced EPCs in both normoxia and hypoxia compared with HUVECs, the CD31-positive populations in both normoxia and hypoxia were sorted using a cell sorter. Induced EPCs were enriched to 97.11 ± 5.17 % and 96.32 ± 4.32 % in normoxia and hypoxia samples at the second sorting times, respectively (Fig. 3d, e).

Sorted induced EPCs were stained with markers for EPCs and expressions were assessed by flow cytometry (Fig. 4). HFs (negative control) were negative for CD31, VEGFR2, CD34, Tie2, and CD45, were slightly positive for NRP1 (11.43 %), and were strongly positive for CXCR4 (95.43 %). Sorted induced EPCs under hypoxia conditions were positive for CD31 (100 %), VEGFR2 (95.31 %), NRP1 (88.89 %), and CXCR4 (100 %), and were negative for CD34, Tie2, and CD45. Sorted induced EPCs in normoxia conditions were also positive for CD31 (100 %), VEGFR2 (40.12 %), NRP1 (95.19 %), and CXCR4 (100 %), and were negative for CD34, Tie2, and CD45. The marker profile of induced EPCs in both normoxia and hypoxia conditions were similar to the HUVEC positive control, with positive expression of CD31 (100 %), VEGFR2 (60.67 %), NRP1 (100 %), and CXCR4 (100 %), and negative expression for CD34, Tie2, and CD45. The marker profiles were similar between normoxia-induced EPCs and hypoxia-induced EPCs.
Fig. 4

ETV2 transduced fibroblasts expressed EPC phenotypes. The transduced cells from both groups (ETV2 + normoxia and ETV2 + hypoxia) exhibited some similar characteristics. They were positive for CD31, CXCR4, and NRP1. VEGFR2 expression was different in the two groups; in hypoxia conditions the transduced cells strongly expressed this marker compared with normoxia conditions. Generally, ETV2 transduced cells in both normoxia and hypoxia conditions exhibited phenotypes similar to HUVECs and different to fibroblasts. HUVEC human umbilical vein endothelial cell

Similar gene expression patterns in induced fibroblasts and HUVECs

To confirm whether induced EPCs were similar to normal EPCs/endothelial cells (with HUVECs as control), several endothelial cell-related genes were evaluated in induced EPCs in both normoxia and hypoxia conditions compared with HUVECs. The results showed that almost all endothelial cell-related genes, including NRP2, NR2F2, EPHB4, JAG1, EFNB2, HEY1, PROX2, and SOX18, were expressed in induced EPCs. These genes were expressed at low levels in HFs, and were strongly expressed in HUVECs. Generally, endothelial cell-related genes significantly increased in ETV2 transduced fibroblasts in both hypoxia and normoxia. However, expression of these genes in transduced cells was lower than in HUVECs. There were some differences in expression of some genes between induced EPCs in hypoxia and normoxia conditions, but these differences were not statistically significant (p > 0.05), except for the EFNB2 gene (Fig. 5).
Fig. 5

Expression of some genes in induced cells compared with HUVECs. (a) NRP2, NR2F2, EPHB4, JAG1, and SOX18. (b) EFNB2, HEY1, and PROX2. Generally almost endothelial cell-related genes significantly increased in ETV2 transduced fibroblasts in both hypoxia and normoxia. However, expression of these genes in transduced cells was lower than in HUVECs. HUVEC human umbilical vein endothelial cell

Formation of capillary-like networks on Matrigel

Induced EPCs were assessed for in-vitro capillary formation in Matrigel. As shown in Fig. 6, induced EPCs in both normoxia and hypoxia conditions could form capillaries similar to HUVECs, while HFs could not form. There was no difference in capillary formation of induced EPCs in normoxia and hypoxia conditions (Fig. 6).
Fig. 6

Capillary-like network on Matrigel by cells in groups. (a) HFs could not form the capillary-like network. (b) ETV2 transduced HFs in both normoxia and hypoxia, successfully forming the capillary-like network (c) similar to HUVECs (d). HUVEC human umbilical vein endothelial cell

VEGF and increased efficacy of reprogramming

We next examined the levels of VEGF in medium from cells cultured in normoxia and hypoxia conditions. The VEGF concentration was significantly increased in the hypoxia culture-derived supernatant compared with the normoxia culture-derived supernatant (5.51 ± 1.43 pg/ml in hypoxia culture vs 1.52 ± 0.41 pg/ml in normoxia culture) (p < 0.05).

We then examined the effects of modulating VEGF concentrations under both conditions. First, the medium in cells cultured under normoxia conditions was supplemented with VEGF (10 ng/ml) and then fibroblasts were virally transduced with ETV2. Addition of VEGF increased the reprogramming efficacy under normoxia conditions from 1.42 ± 0.32 % of CD31-positive cells in medium without VEGF (Figs. 7b and 8a–e) to 9.56 ± 3.12 % of CD31-positive cells in medium with VEGF (Figs. 7c and 8f–j) compared with 0 % in fibroblasts (Fig. 7a).
Fig. 7

CD31-positive cells analyzed by flow cytometry. As a negative control, HFs did not contain the CD31+ population (a). In the normoxia condition, ETV2 transduced HFs contained a small CD31+ cell population (b). A larger population of CD31+ cells was present in ETV2 transduced HFs under hypoxia (d), similar to the ETV2 transduced HFs under normoxia supplemented with VEGF (c). The percentage of CD31+ cells significantly decreased in the ETV2 transduced HFs under hypoxia supplemented with anti-VEGF monoclonal antibody (e). VEGF vascular endothelial growth factor. SSC Side Scatter

Fig. 8

CD31 expression in ETV2 transduced fibroblasts. ETV2 transduction under the hypoxia condition (pt) significantly increased CD31+ cells compared with normoxia (ae), but significantly decreased if the medium was supplemented with anti-VEGF monoclonal antibodies (ko). In the normoxia condition, adding VEGF to the medium culture of ETV2 transduced cells could significantly increase the CD31+ cells (fj). VEGF vascular endothelial growth factor

We next supplemented cells in hypoxia culture with an anti-VEGF antibody and found that the reprogramming efficacy was lower in anti-VEGF antibody-treated hypoxic cells (2.14 ± 0.49 % CD31-positive cells, Figs. 7e and 8k–o) compared with 5.54 ± 2.13 % CD31-positive cells under hypoxia conditions (Figs. 7d and 8p–t).

Discussion

EPCs are considered an important cell source for vascular regeneration. However, isolation of EPCs from umbilical cord blood, peripheral blood, and bone marrow has not been successful owing to low numbers of EPCs in these blood sources. Many studies have therefore examined strategies to improve the proliferation and expansion of these cells. Other groups have pursued the direct reprogramming of fibroblasts into EPCs. Recent reports using ETV2 transfection showed that HFs could be directly reprogrammed into endothelial cells or EPCs. However, these preliminary studies showed that reprogramming of fibroblasts to endothelial cells or EPCs was low. In this study, we successfully increased the reprogramming efficacy by hypoxia treatment.

ETV2 overexpression can cause the differentiation of stem cells into endothelial cells. ETV2 is a master gene that regulates various signaling pathways and functions as an essential regulator for vasculogenesis and hematopoiesis. ETV2 interacts with GATA2 in endothelial and hematopoietic cells in the early stages of embryogenesis. ETV2 and GATA2 bind to the promoter of SPI1 and regulate its expression during embryogenesis [43]. Therefore, in a recent study, Liu et al. [51] could induce the hematopoietic and endothelial cell program by overexpression of ETV2. The authors showed that ETV2 could activate ETS genes, resulting in initiation of the hematopoietic and endothelial cell program. ETV2 has also been suggested as a direct regulator of Sox7 [52]. Overexpression of ETV2 in embryonic bodies resulted in enhanced and increased angiogenesis, while knockdown of ETV2 by shRNA significantly decreased angiogenesis [52]. ETV2 also regulates cardiac development [44], and a recent study showed that ETV2 is also an essential factor for vascular regeneration [45].

Elcheva et al. [53] successfully induced human pluripotent stem cells into hematoendothelial cells using ETV2 transfection. Lindgren et al. [54] confirmed that addition of exogenous ETV2 to human ESCs significantly increased the number of cells expressing angioblast genes. Etv2 alone is required for early vasculogenesis, whereas Etv2 and Fli1b function redundantly during late vasculogenesis and early embryonic angiogenesis [55]. With the important role of ETV2 in both early embryogenesis and vascular regeneration in the adult, some initial studies could only use this factor to direct reprogramming of fibroblasts to endothelial cells.

Our results showed that after 14 days of reprogramming with ETV2 transduction, HFs exhibited specific properties of EPCs/endothelial cells, including strong expression of CD31, VEGFR2, and NRP1. Induced EPCs also expressed a gene profile similar to that in HUVECs. More importantly, these sorted induced EPCs with CD31 expression could form capillary-like networks in vitro in Matrigel. Together these phenotypes confirmed that ETV2 transduced fibroblasts were functional EPCs.

Our study also showed that hypoxia markedly affected reprogramming efficacy. Hypoxia treatment during the reprogramming procedure increased the number of cells converted to EPCs. However, hypoxia in combination with ETV2 transfection did not affect the induced EPC phenotypes.

We next considered the mechanisms by which hypoxia could increase the reprogramming of ETV2 transduced fibroblasts into EPCs. We observed a marked difference in VEGF concentration in supernatants from hypoxia and normoxia cultured cells, suggesting that VEGF may be the main factor contributing to the increased efficacy of cell reprogramming. In fact, our results showed that HFs produced over 3-fold more VEGF under hypoxia conditions compared with cells in the normoxia condition, which is similar to previously published studies [5661]. This observation also was recorded in some stem cells that could increase the production of VEGF under hypoxia [6264].

To determine whether VEGF is a main factor affecting reprogramming efficacy, we supplemented VEGF in the culture medium under normoxia conditions and found that reprogramming efficacy was increased compared with cells without additional VEGF. Moreover, reprogramming efficacy in hypoxia conditions decreased when cells were supplemented with anti-VEGF monoclonal antibody. We thus concluded that VEGF is the main factor involved in the direct reprogramming of fibroblasts into EPCs by ETV2 transduction.

Conclusion

EPCs are important cells for angiogenesis and ischemia-related disease treatments. However, EPCs are rare cells in peripheral blood, bone marrow, and umbilical cord blood. Here, we showed that single-factor ETV2 transduction was a simple approach to produce EPCs from fibroblasts. Notably, ETV2 transduction in combination with hypoxia treatment resulted in increased efficacy of reprogramming from fibroblasts to EPCs. These induced EPCs exhibited EPC phenotypes and could form capillary networks in vitro, similar to human umbilical endothelial cells. These findings suggest a simple strategy to increase the reprogramming efficacy from fibroblasts to EPCs.

Abbreviations

CD, cluster of differentiation; EPC, endothelial progenitor cell; ETV2, E26 transformation-specific Ets Variant 2; HF, human fibroblast; HUVEC, human umbilical vein endothelial cell; iPSC, induced pluripotent stem cell; PBS, phosphate-buffered saline; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2

Declarations

Acknowledgements

This research was funded by the Vietnam National Foundation for Science and Technology Development (NAFOSTED) under grant number 106-YS.06-2013.37.

Authors’ contributions

PVP was responsible for suggesting the idea for this study, creating the experiment design, vector preparation, data analysis, writing the Discussion, preparing the figures, and revising the manuscript. NBV was responsible for performing the essays of fibroblast culture, RT-PCR analysis, flow cytometry analysis, and writing the Methods. HTN was responsible for performing the HUVEC cultures, Matrigel assays, and writing the Introduction. OTH and MT-HT were responsible for producing the viral virus vector, fibroblast culture, and cell sorting, and writing the Results. All authors read and approved the manuscript.

Competing interests

The authors declare they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratory of Stem Cell Research and Application, University of Science, Viet Nam National University

References

  1. Bogoslovsky T, et al. Preservation and enumeration of endothelial progenitor and endothelial cells from peripheral blood for clinical trials. Biomark Med. 2015;9(7):625–37.View ArticlePubMedGoogle Scholar
  2. Shaffer RG, et al. Flow cytometric measurement of circulating endothelial cells: the effect of age and peripheral arterial disease on baseline levels of mature and progenitor populations. Cytometry B Clin Cytom. 2006;70(2):56–62.View ArticlePubMedGoogle Scholar
  3. Tasev D, et al. Long-term expansion in platelet lysate increases growth of peripheral blood-derived endothelial-colony forming cells and their growth factor-induced sprouting capacity. PLoS One. 2015;10(6):e0129935.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Colombo E, et al. Comparison of fibronectin and collagen in supporting the isolation and expansion of endothelial progenitor cells from human adult peripheral blood. PLoS One. 2013;8(6):e66734.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Asahara T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–6.View ArticlePubMedGoogle Scholar
  6. D’Avola D, et al. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow-derived endothelial progenitor cells. Transl Res. 2016;S1931-5244(16)00063-3.Google Scholar
  7. Donndorf P, et al. Mobilization of bone marrow-derived endothelial progenitor cells following Finnish sauna: a pilot study. Forsch Komplementmed. 2015;22(4):246–50.View ArticlePubMedGoogle Scholar
  8. Bai YY, et al. Bone marrow endothelial progenitor cell transplantation after ischemic stroke: an investigation into its possible mechanism. CNS Neurosci Ther. 2015;21(11):877–86.View ArticlePubMedGoogle Scholar
  9. Kim SW, et al. Therapeutic effects of late outgrowth endothelial progenitor cells or mesenchymal stem cells derived from human umbilical cord blood on infarct repair. Int J Cardiol. 2016;203:498–507.View ArticlePubMedGoogle Scholar
  10. Kim J, et al. BMP9 induces cord blood-derived endothelial progenitor cell differentiation and ischemic neovascularization via ALK1. Arterioscler Thromb Vasc Biol. 2015;35(9):2020–31.View ArticlePubMedGoogle Scholar
  11. Peters EB, et al. Umbilical cord blood-derived mononuclear cells exhibit pericyte-like phenotype and support network formation of endothelial progenitor cells in vitro. Ann Biomed Eng. 2015;43(10):2552–68.View ArticlePubMedGoogle Scholar
  12. Phuc PV, et al. Isolation of three important types of stem cells from the same samples of banked umbilical cord blood. Cell Tissue Bank. 2012;13(2):341–51.View ArticlePubMedGoogle Scholar
  13. Hu CH, et al. Human umbilical cord-derived endothelial progenitor cells promote growth cytokines-mediated neorevascularization in rat myocardial infarction. Chin Med J (Engl). 2009;122(5):548–55.Google Scholar
  14. Hu CH, et al. Expanded human cord blood-derived endothelial progenitor cells salvage infarcted myocardium in rats with acute myocardial infarction. Clin Exp Pharmacol Physiol. 2010;37(5–6):551–6.View ArticlePubMedGoogle Scholar
  15. Schuh A, et al. Transplantation of endothelial progenitor cells improves neovascularization and left ventricular function after myocardial infarction in a rat model. Basic Res Cardiol. 2008;103(1):69–77.View ArticlePubMedGoogle Scholar
  16. Kalka C, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000;97(7):3422–7.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Kawamoto A, et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation. 2003;107(3):461–8.View ArticlePubMedGoogle Scholar
  18. Suh W, et al. Transplantation of endothelial progenitor cells accelerates dermal wound healing with increased recruitment of monocytes/macrophages and neovascularization. Stem Cells. 2005;23(10):1571–8.View ArticlePubMedGoogle Scholar
  19. Cha SK, et al. Effect of human endothelial progenitor cell (EPC)- or mouse vascular endothelial growth factor-derived vessel formation on the survival of vitrified/warmed mouse ovarian grafts. Reprod Sci. 2014;21(7):859–68.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Haller C, et al. One-staged aptamer-based isolation and application of endothelial progenitor cells in a porcine myocardial infarction model. Nucleic Acid Ther. 2015;25(1):20–6.View ArticlePubMedGoogle Scholar
  21. Losordo DW, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007;115(25):3165–72.View ArticlePubMedGoogle Scholar
  22. Losordo DW, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109(4):428–36.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Povsic TJ, et al. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J. 2013;165(6):854–61. e2.Google Scholar
  24. Losordo DW, et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv. 2012;5(6):821–30.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Li SH, et al. Exogenous hTERT gene transfected endothelial progenitor cells from bone marrow promoted angiogenesis in ischemic myocardium of rats. Int J Clin Exp Med. 2015;8(8):14447–53.PubMedPubMed CentralGoogle Scholar
  26. She Q, et al. Angiogenesis in a rat model following myocardial infarction induced by hypoxic regulation of VEGF(1)(6)(5) gene-transfected EPCs. Mol Med Rep. 2012;6(6):1281–7.PubMedGoogle Scholar
  27. Long J, et al. The therapeutic effect of vascular endothelial growth factor gene- or heme oxygenase-1 gene-modified endothelial progenitor cells on neovascularization of rat hindlimb ischemia model. J Vasc Surg. 2013;58(3):756–65. e2.Google Scholar
  28. Yu JX, et al. Combination of stromal-derived factor-1alpha and vascular endothelial growth factor gene-modified endothelial progenitor cells is more effective for ischemic neovascularization. J Vasc Surg. 2009;50(3):608–16.View ArticlePubMedGoogle Scholar
  29. Flex A, et al. Human cord blood endothelial progenitors promote post-ischemic angiogenesis in immunocompetent mouse model. Thromb Res. 2016;141:106–11.View ArticlePubMedGoogle Scholar
  30. Asahara T, Kalka C, Isner JM. Stem cell therapy and gene transfer for regeneration. Gene Ther. 2000;7(6):451–7.View ArticlePubMedGoogle Scholar
  31. Yoder MC. Differentiation of pluripotent stem cells into endothelial cells. Curr Opin Hematol. 2015;22(3):252–7.View ArticlePubMedPubMed CentralGoogle Scholar
  32. White MP, et al. Limited gene expression variation in human embryonic stem cell and induced pluripotent stem cell-derived endothelial cells. Stem Cells. 2013;31(1):92–103.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Wang L, et al. Gene and microRNA profiling of human induced pluripotent stem cell-derived endothelial cells. Stem Cell Rev. 2015;11(2):219–27.View ArticlePubMedGoogle Scholar
  34. Park SJ, et al. A comparison of human cord blood- and embryonic stem cell-derived endothelial progenitor cells in the treatment of chronic wounds. Biomaterials. 2013;34(4):995–1003.View ArticlePubMedGoogle Scholar
  35. Kimbrel EA, Lanza R. Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat Rev Drug Discov. 2015;14(10):681–92.View ArticlePubMedGoogle Scholar
  36. Simonson OE, et al. The safety of human pluripotent stem cells in clinical treatment. Ann Med. 2015;47(5):370–80.View ArticlePubMedGoogle Scholar
  37. Margariti A, et al. Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels. Proc Natl Acad Sci U S A. 2012;109(34):13793–8.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Li J, et al. Conversion of human fibroblasts to functional endothelial cells by defined factors. Arterioscler Thromb Vasc Biol. 2013;33(6):1366–75.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Han JK, et al. Direct conversion of adult skin fibroblasts to endothelial cells by defined factors. Circulation. 2014;130(14):1168–78.View ArticlePubMedGoogle Scholar
  40. Lee S, et al. Direct reprogramming of human dermal fibroblasts into endothelial cells using a single transcription factor. Circulation. 2014;130 Suppl 2:A18205.Google Scholar
  41. Morita R, et al. ETS transcription factor ETV2 directly converts human fibroblasts into functional endothelial cells. Proc Natl Acad Sci U S A. 2015;112(1):160–5.View ArticlePubMedGoogle Scholar
  42. Ginsberg M, et al. Efficient direct reprogramming of mature amniotic cells into endothelial cells by ETS factors and TGFbeta suppression. Cell. 2012;151(3):559–75.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Shi X, et al. Cooperative interaction of Etv2 and Gata2 regulates the development of endothelial and hematopoietic lineages. Dev Biol. 2014;389(2):208–18.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Schupp MO, et al. Transcriptional inhibition of etv2 expression is essential for embryonic cardiac development. Dev Biol. 2014;393(1):71–83.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Park C, et al. Injury-mediated vascular regeneration requires endothelial ER71/ETV2. Arterioscler Thromb Vasc Biol. 2016;36(1):86–96.View ArticlePubMedGoogle Scholar
  46. Foja S, et al. Hypoxia supports reprogramming of mesenchymal stromal cells via induction of embryonic stem cell-specific microRNA-302 cluster and pluripotency-associated genes. Cell Reprogram. 2013;15(1):68–79.PubMedGoogle Scholar
  47. Shimada H, et al. Accelerated generation of human induced pluripotent stem cells with retroviral transduction and chemical inhibitors under physiological hypoxia. Biochem Biophys Res Commun. 2012;417(2):659–64.View ArticlePubMedGoogle Scholar
  48. Yoshida Y, et al. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell. 2009;5(3):237–41.View ArticlePubMedGoogle Scholar
  49. Iida K, et al. Hypoxia-enhanced derivation of iPSCs from human dental pulp cells. J Dent Res. 2013;92(10):905–10.View ArticlePubMedGoogle Scholar
  50. Nahm WK, Zhou L, Falanga V. Sustained ability for fibroblast outgrowth from stored neonatal foreskin: a model for studying mechanisms of fibroblast outgrowth. J Dermatol Sci. 2002;28(2):152–8.View ArticlePubMedGoogle Scholar
  51. Liu F, et al. Induction of hematopoietic and endothelial cell program orchestrated by ETS transcription factor ER71/ETV2. EMBO Rep. 2015;16(5):654–69.View ArticlePubMedPubMed CentralGoogle Scholar
  52. Behrens AN, et al. Sox7 is regulated by ETV2 during cardiovascular development. Stem Cells Dev. 2014;23(17):2004–13.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Elcheva I, et al. Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators. Nat Commun. 2014;5:4372.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Lindgren AG, Veldman MB, Lin S. ETV2 expression increases the efficiency of primitive endothelial cell derivation from human embryonic stem cells. Cell Regen (Lond). 2015;4(1):1.View ArticleGoogle Scholar
  55. Craig MP, et al. Etv2 and fli1b function together as key regulators of vasculogenesis and angiogenesis. Arterioscler Thromb Vasc Biol. 2015;35(4):865–76.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Zhang Z, et al. The effects of conditioned medium from keloid fibroblasts under hypoxia on angiogenesis. Zhonghua Zheng Xing Wai Ke Za Zhi. 2014;30(4):283–8.PubMedGoogle Scholar
  57. Jackson J, et al. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol. 1997;24(7):1253–9.PubMedGoogle Scholar
  58. Minchenko A, et al. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest. 1994;71(3):374–9.PubMedGoogle Scholar
  59. Hitchon C, et al. Hypoxia-induced production of stromal cell–derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum. 2002;46(10):2587–97.View ArticlePubMedGoogle Scholar
  60. Steinbrech DS, et al. Fibroblast response to hypoxia: the relationship between angiogenesis and matrix regulation. J Surg Res. 1999;84(2):127–33.View ArticlePubMedGoogle Scholar
  61. Steinbrech DS, et al. Hypoxia upregulates VEGF production in keloid fibroblasts. Ann Plast Surg. 1999;42(5):514–20.View ArticlePubMedGoogle Scholar
  62. Lee EY, et al. Hypoxia-enhanced wound-healing function of adipose-derived stem cells: increase in stem cell proliferation and up-regulation of VEGF and bFGF. Wound Repair Regen. 2009;17(4):540–7.View ArticlePubMedGoogle Scholar
  63. Rehman J, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004;109(10):1292–8.View ArticlePubMedGoogle Scholar
  64. Van Pham P, et al. Hypoxia condition promoted the adipose derived stem cell proliferation via VEGF production. Biomed Res Ther. 2016;3(1):476-82.Google Scholar

Copyright

© The Author(s). 2016

Advertisement